Treatment with the EGFR inhibitor Gefitinib or EGFR/HER2 inhibitor Lapatinib resulted in a decrease in the number of papillomas by 88% and 50%, respectively, and restored the number of cSCCs back to Tpl2+/+ levels. Here, EGFR is linked to papilloma.